Sponsored
Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time prevention—protecting billions in copay spend while ensuring support reaches the patients who need it most.
Cindy Baksh, ConnectiveRx
Advertisement
Articles by Cindy Baksh, ConnectiveRx
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Why Do a Significant Number of GLP-1 Users Stop Taking the Medication in the First Year?
2
New Federal Market Access Restrictions: Optimizing Manufacturer Strategies as PBMs Gain Power
3
How Many GLP-1 Users Must Seek Medical Care for Side Effects?
4
World Health Day 2026: Quotes that Stand with Science
5